Skip to main content
Terug
Watch Compare

Quince Therapeutics, Inc.

Datakwaliteit: 83%
QNCX
NASDAQ Manufacturing Chemicals
€ 1,34
▲ € 0,11 (8,94%)
6 months return
—
Momentum
Neutral
ROE
-890,64%

Groei

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-890,64%
Onder sectorgemiddelde (-54,47%)
ROIC-41,40%
Net MarginN/A
Op. MarginN/A

Veiligheid

Debt / Equity
0,00
Onder sectorgemiddelde (0,30)
Current Ratio1,12
Interest CoverageN/A

Waardering

PE (TTM)
-0,12
Boven sectorgemiddelde (-1,50)
P/B Ratio6,50
EV/EBITDAN/A
Dividend YieldN/A

Quick Summary

Key Takeaways

Short bullets derived from reported financials—not the AI summary above.

Debt/Equity of 0,00 — conservative balance sheet
Negative free cash flow of -38,98 M

Price History

Financiële Trends

Koersdoel Analisten

1 analist
Hold
-100.0%
upside to target
Huidig
€ 1,34
Consensus Target
€ 0,00
€ 0,00
Laag
€ 0,00
Hoog
Vooruitzicht
Forward WPA
-€ 2,70
Omzet Sch.
25,58 M

Winstverassingen

EPS
Reported Estimate Forecast
Next: Q1 2026 · EPS Est: -€ 2,30 · Rev Est: 0,0
Q42024 Q12025 Q22025 Q32025 Q42025 Q1 '26 Q2 '26
Reported -€ 0,28 -€ 3,40 -€ 3,25 -€ 2,50 -€ 7,60 — —
Estimate -€ 0,10 -€ 2,30 -€ 2,33 -€ 2,23 -€ 2,25 -€ 2,30 -€ 2,30
Verrassing -180,00% -47,83% -39,83% -12,36% -237,78% — —

Growth

Rev 5Y: N/A · Earnings 1Y: N/A
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A

Profitability

ROE: -890,64% · Net Margin: N/A
Revenue (TTM) N/A Net Income (TTM) -56,98 M
ROE -890,64% ROA -50,18%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -38,98 M
ROIC -41,40% FCF Growth (3Y) N/A

Safety

D/E: 0,00 · Current: 1,12
Debt / Equity 0,00 Current Ratio 1,12
Interest Coverage N/A Asset Turnover N/A
Working Capital 3,16 M Tangible Book Value -66,67 M

Dividends

Yield: N/A · Payout: N/A
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A

Valuation

P/E: -0,12 · EV/EBITDA: N/A
P/E Ratio -0,12 Forward P/E N/A
P/B Ratio 6,50 P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S 0,27 Fwd Earnings Yield N/A
FCF Yield -565,88%
Market Cap 6,89 M Enterprise Value 435.800,0

Per Share

EPS: -1,20 · FCF/Share: -0,70
EPS (Diluted TTM) -1,20 Revenue / Share N/A
FCF / Share -0,70 OCF / Share -0,69
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A

Efficiency

FCF Conv: 68,41% · CapEx/Rev: N/A
CapEx / Revenue N/A FCF Conversion 68,41%
SBC-Adj. FCF -44,02 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2024 FY2023 FY2022 FY2021 FY2020
Revenue — — — — —
Net Income -56,83 M -31,39 M -51,66 M -89,95 M -76,85 M
EPS (Diluted) -1,31 -0,84 -1,54 — —
Gross Profit — — — — —
Operating Income -57,29 M -34,62 M -52,02 M -90,32 M -78,89 M
EBITDA — — — — —
R&D Expenses 18,59 M 9,45 M 25,18 M 60,80 M 61,31 M
SG&A Expenses — — — — —
D&A 186.000,0 322.000,0 204.000,0 344.000,0 332.000,0
Interest Expense — — — — 957.000,0
Income Tax 87.000,0 197.000,0 -284.000,0 — 0,0

Balance Sheet

Annual, most recent first
Metric FY2024 FY2023 FY2022 FY2021 FY2020
Total Assets 114,48 M 167,90 M 103,91 M 133,23 M 189,47 M
Total Liabilities 84,33 M 82,82 M 3,32 M 14,64 M 17,20 M
Shareholders' Equity 30,15 M 85,08 M 100,59 M 118,59 M 172,26 M
Total Debt 14,32 M 13,43 M — — —
Cash & Equivalents 40,80 M 75,10 M 90,20 M 106,80 M 133,80 M
Current Assets 44,04 M 77,44 M 93,75 M 111,67 M 137,86 M
Current Liabilities 7,28 M 9,57 M 3,07 M 14,22 M 17,00 M

Sectorvergelijking

vs Manufacturing sector mediaan (1605 peers)
Metriek Aandeel Sector Mediaan
P/E -0,1 -1,5
P/B 6,5 1,6
ROE % -890,6 -54,5
Net Margin % — -41,5
Rev Growth 5Y % — 1,9
D/E 0,0 0,3

ETFs Holding This Stock
BRSIX BRSIX
0,10% weight